Valuation: GENFIT

Market Cap 645M 737M 596M 548M 1.03B 71.06B 1.06B 7.11B 2.8B 34.81B 2.77B 2.71B 120B P/E 2026 *
67.8x
P/E 2027 * 85.7x
Enterprise Value 594M 679M 549M 505M 952M 65.43B 974M 6.55B 2.58B 32.05B 2.55B 2.49B 110B EV / Sales 2026 *
5.93x
EV / Sales 2027 * 4.67x
Free-Float
86.88%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 2019-09-15
Director of Finance/CFO 52 2021-04-21
Chief Tech/Sci/R&D Officer - 2025-11-26
Director TitleAgeSince
Chairman 70 2017-06-15
Director/Board Member 54 1999-09-14
Director/Board Member 58 2017-06-15
Change 5-day change 1-year change 3-year change Capi.($)
-1.29%-3.11%-0.35%+3.09% 49.18B
+3.90%-0.39%+386.06%+593.85% 39.58B
-1.70%+4.46%+5.93%+60.25% 34.69B
-2.01%-0.76%+28.41%-8.01% 34.42B
+0.06%+0.34%+2.38%+34.38% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+115.55% 15.36B
+1.12%+1.91%+14.54%+19.16% 14.05B
0.00%+1.36%+18.43%-30.79% 13.02B
Average +0.06%+0.03%+65.98%+98.43% 27.07B
Weighted average by Cap. -0.05%-0.18%+79.44%+123.32%

Financials

2026 *2027 *
Net sales 100M 114M 92.55M 85.16M 161M 11.03B 164M 1.1B 434M 5.4B 430M 421M 18.61B 124M 142M 115M 105M 199M 13.66B 203M 1.37B 538M 6.69B 532M 521M 23.04B
Net income 22.88M 26.14M 21.13M 19.44M 36.65M 2.52B 37.49M 252M 99.15M 1.23B 98.16M 96.03M 4.25B 6.8M 7.77M 6.28M 5.78M 10.89M 749M 11.14M 74.95M 29.47M 367M 29.18M 28.54M 1.26B
Net Debt -51.12M -58.41M -47.22M -43.45M -81.89M -5.63B -83.76M -563M -222M -2.76B -219M -215M -9.49B -66.17M -75.62M -61.12M -56.24M -106M -7.29B -108M -729M -287M -3.57B -284M -278M -12.29B
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-